MenB and MenACWY programmes: a video training guide for healthcare professionals
Updated 2 September 2015
© Crown copyright 2015
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/menb-and-menacwy-programmes-training-guide/menb-and-menacwy-programmes-a-video-training-guide-for-healthcare-professionals
A training resource for healthcare professionals on the MenB and MenACWY immunisation programmes, to use along-side the advanced training slide set.
The MenACWY vaccine is being introduced in response to an increase in cases of invasive meningococcal disease capsular group W (MenW) disease.This vaccine will provide direct protection to the vaccinated cohort and, by reducing carriage of MenW, will also provide indirect protection to unvaccinated children and adults.
The new MenB vaccine (Bexsero®) will protect against meningococcal disease capsular group B. The vaccine will be added to the childhood immunisation programme as part of the routine schedule in England from 1 September 2015.
1. What meningococcal disease is
Dr. Mary Ramsay, Head of Immunisation at Public Health England (PHE) explains the scientific background to the changes to the childhood immunisation schedule to protect against meningococcal disease (slides 3-11).
What is meningococcal disease?
2. The MenB vaccine (Bexero®)
Dr. Shamez Ladhani, Paediatric Infectious Diseases consultant in the immunisation department of PHE explains the scientific research and development behind the new MenB vaccine for infants (slides 12-20).
What is the MenB vaccine (Bexero®)?
3. Who we should vaccinate
Dr. Mary Ramsay provides an explanation of the epidemiological background to the changes in vaccinating to protect against meningococcal disease (slides 21-37).
4. How we are implementing the new MenB infant immunisation programme
Matthew Olley, immunisation nurse specialist in the immunisation department of PHE explains the details of the infant immunisation programme and how it is going to be delivered (slides 28-39).
How are we implementing the new MenB infant immunisation programme?
5. How we can prevent fever after the MenB vaccination
Dr. Shamez Ladhani explains how healthcare professionals will support the management of fever after MenB vaccination (slides 40-61).
How can we prevent fever after the MenB vaccination?
6. How we can control the increase in MenW disease
Dr. Mary Ramsay explains how the vaccination programme aims to control MenW disease (slides 62-74).
How can we control the increase in Meningococcal group W disease?
7. Which MenACWY conjugate vaccines to use
Matthew Olley provides details of the MenACWY vaccine (slides 75-88).
Which MenACWY conjugate vaccines should we use?
8. How we will implement the teenage MenACWY programme
Dr. Shamez Ladhani explains the details of the teenage immunisation programme and how it is going to be delivered (slides 89-95).
How will we implement the teenage MenACWY programme?
9. How we will monitor the programmes
Slides 96 to 106 explain the methods of monitoring the two new programmes:
- identifying and reporting the notifiable infections
- the follow up process of meningococcal cases
- using the yellow card scheme and CHIS reporting system
10. Additional resources
Additional information on the MenB and MenACWY programmes can be found in slides 107-116, the immunisation collection and the below footage from the PHE’s 2015 national immunisation network meeting.
10.1 2015 National immunisation network meeting
Additional information on MenB
The role of paracetamol in the MenB programme
Implementing the MenB and MenACWY programmes
10.2 MenB and Paracetamol
Public Health England has been working closely with Oxford Vaccine Group who have produced a mock video consultation including a discussion between a practice nurse and patient about the use of paracetamol following MenB vaccination. This is a key training resource for frontline immunisers to ensure that parents receive the necessary information on the increased risk of fever and correct use of paracetamol following the two and fourth month appointment visits. Local NHS England and PHE colleagues are requested to help to cascade this training locally to frontline immunisers.
MenB and Paracetamol consultation
10.3 Further information and training materials on the MenB and MenACWY immunisation programmes are available.
‘Immunisation against infectious disease’, also known as the Green Book, has the latest information on vaccines and vaccination procedures in the UK.
Immunisation patient group direction (PGD) templates are available for authorisation and adoption to provide NHS England Commissioned national routine immunisation services.
Vaccine update newsletters cover developments in the field and updates to the Green Book.